NeuroPace, Inc. (NPCE) announced that its NAUTILUS study did not reach statistical significance for the primary effectiveness endpoint, causing its stock price to fall 28.39%. Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by the company and its officers.

NeuroPace, a medical device company focused on epilepsy treatment, announced that its management team will present at the Leerink Partners 2025 Global Healthcare Conference.

The neuroscience market is rapidly expanding, driven by growing awareness of neurological disorders and advancements in medical research and technology. Key investments from public and private sectors, along with the integration of advanced technologies like Brain-Computer Interfaces, AI, and machine learning, are transforming the neuroscience landscape and creating new market opportunities.

Globus Medical (GMED) delivered earnings and revenue surprises of 30.91% and 3.41%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2024 after market close on Wednesday, May 8, 2024. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

MOUNTAIN VIEW, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will present at the Needham 23rd Annual Healthcare Conference, taking place virtually from April 8-11.

Analysts' ratings for NeuroPace (NASDAQ:NPCE) over the last quarter vary from bullish to bearish, as provided by 6 analysts. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 2 0 0 Last 30D 0 1 0 0 0 1M Ago 0 1 2 0 0 2M Ago 0 1 0 0 0 3M Ago 1 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for NeuroPace, presenting an average target of $16.33, a high estimate of $22.00, and a low estimate of $12.00. Observing a 48.45% increase, the current average has risen from the previous average price target of $11.00. Analyzing Analyst Ratings: A Detailed Breakdown The standing of NeuroPace among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Robbie Marcus JP Morgan Raises Overweight $17.00 $9.00 Ross Osborn Cantor Fitzgerald Raises Overweight $18.00 $16.00 Drew Ranieri Morgan Stanley Raises Equal-Weight $13.00 $9.00 Lawrence Biegelsen Wells Fargo Raises Equal-Weight $16.00 $9.00 Mike Kratky Leerink Partners Announces Outperform $22.00 - Frank Takkinen Lake Street Maintains Buy $12.00 $12.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related ...Full story available on Benzinga.com

-- Revenue increased to $18.0 million in Q4 2023, a 41% increase over Q4 2022 -- -- Revenue increased to $65.4 million in 2023, a 44% increase over 2022 --

Throughout the last three months, 4 analysts have evaluated NeuroPace (NASDAQ:NPCE), offering a diverse set of opinions from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 2 0 0 Last 30D 0 0 1 0 0 1M Ago 0 1 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 1 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $14.75, with a high estimate of $22.00 and a low estimate of $9.00. Observing a 52.53% increase, the current average has risen from the previous average price target of $9.67. Decoding Analyst Ratings: A Detailed Look A comprehensive examination of how financial experts perceive NeuroPace is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Lawrence Biegelsen Wells Fargo Raises Equal-Weight $16.00 $9.00 Mike Kratky Leerink Partners Announces Outperform $22.00 - Frank Takkinen Lake Street Maintains Buy $12.00 $12.00 Drew Ranieri Morgan Stanley Raises Equal-Weight $9.00 $8.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response ...Full story available on Benzinga.com

MOUNTAIN VIEW, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Tuesday, March 5, 2024. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

NeuroPace (NASDAQ:NPCE) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 2 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 1 0 0 3M Ago 0 2 1 0 0 Analysts have recently evaluated NeuroPace and provided 12-month price targets. The average target is $11.83, accompanied by a high estimate of $22.00 and a low estimate of $8.00. This upward trend is apparent, with the current average reflecting a 47.88% increase from the previous average price target of $8.00. Deciphering Analyst Ratings: An In-Depth Analysis A comprehensive examination of how financial experts perceive NeuroPace is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Mike Kratky Leerink Partners Announces Outperform $22.00 - Frank Takkinen Lake Street Maintains Buy $12.00 $12.00 Drew Ranieri Morgan Stanley Raises Equal-Weight $9.00 $8.00 Drew Ranieri Morgan Stanley Raises Equal-Weight $8.00 $6.00 Ross Osborn Cantor Fitzgerald Announces Overweight $11.00 - Robbie Marcus JP Morgan Raises Overweight $9.00 $6.00 Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments ...Full story available on Benzinga.com

Preliminary unaudited revenue expected to be between $17.5 million and $18.0 million for Q4 2023 and between $64.9 million and $65.4 million for full year 2023